Data show that simufilam reduced seizure activity in a preclinical mouse model Presentation also highlights favorable human ...

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June 26-28, 2025 in ...

Cassava Sciences’ stock (NASDAQ: SAVA) plummeted on Monday by a staggering 85%. “The results are disappointing for patients and their families who are living with this disease and physicians ...

Investment Overview. The share price of Cassava Sciences (NASDAQ:SAVA) increased from ~$1, to $10 between 2019 and 2020, tread water between 2020 and 2021, had increased in value to >$120 by ...

Get the latest news on Cassava Sciences stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on SAVA performance ...

After surging from $7 per share to around $120 per share this year, Cassava Sciences (NASDAQ:SAVA) stock may not have room to make more “to the moon” moves higher. Source: Atthapon Raksthaput ...

Shares of Cassava Sciences (SAVA 2.83%) skyrocketed in the first half of 2021. The biotech's share price ran up 1,152% from the first of January to the end of June.

Cassava Sciences has a better product, better data and will be a better value for AD patients. Cassava's New Approach with a Unique Mechanism of Action.

Investing in Cassava Sciences (NASDAQ:SAVA) makes sense based on its fundamental financial position, but it remains a gamble. The company has run up against serious allegations in pursuit of Food ...

The market's been in love with Cassava Sciences (SAVA 2.83%) all year, but it's definitely a rocky relationship. The stock soared from $8 a share back in January to $126 on Aug. 12.